Condition: Graves Disease · Thyroid Cancer · Sponsor: University of Ulm
The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism. Patients will be included in whom thyroid hormone levels are intentionally changed by treatment. In patients with Graves' disease, thyroid hormone levels will be lowered using medication, while in patients with thyroid cancer, thyroid hormone levels will be raised using medication. Oral glucose tolerance tests will be performed before treatment and at two time points after treatment begins to assess metabolic effects.
This description comes directly from the study's public registry record.
Martin Heni, Prof · +4973150044505 · martin.heni@uniklinik-ulm.de
Roza Sabia, MD · +4973150044719 · roza.sabia@uniklinik-ulm.de
Always discuss trial participation with your own doctor first.
| Ulm University Hospital | Ulm, Baden-Wurttemberg, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07410637